Pediatric cancer biotech Y-mAbs Therapeutics Inc. priced its initial public offering late Thursday at $16 a share, selling 6 million shares to raise $96 million. Shares will start trading later Friday on Nasdaq, under the ticker symbol “YMAB”. BofA Merrill Lynch and Cowen were joint bookrunners on the deal with Canaccord Genuity acting as lead manager and BTIG acting as co-manager.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Latest posts by Market Watch (see all)
- London Markets: London markets falter as investors react to historic Brexit defeat - January 16, 2019
- The Wall Street Journal: American among 15 dead after militants attack upscale hotel in Kenya - January 16, 2019
- FTSE 100 slips after historic Brexit defeat - January 16, 2019